Torrent Pharmaceuticals reported a robust 20% year-on-year growth in net profit for the first quarter of FY26, reaching Rs. 548 crore. The surge was primarily propelled by solid performance in the domestic market and sustained traction in the U.S. generics segment. Revenue also saw a healthy uptick, supported by improved operational efficiencies and favorable product mix. The company's strategic focus on high-margin therapies, coupled with disciplined cost control and increased investments in R&D, is expected to sustain its growth momentum through the remainder of the fiscal year.